Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desflurane
Drug ID BADD_D00611
Description Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]
Indications and Usage Desflurane is indicated for the induction and maintenance of anesthesia in adults, as well as the maintenance of anesthesia in pediatric patients.[L30285]
Marketing Status approved
ATC Code N01AB07
DrugBank ID DB01189
KEGG ID D00546
MeSH ID D000077335
PubChem ID 42113
TTD Drug ID D0H4GN
NDC Product Code 0404-9961; 52584-641; 66794-021; 0781-6172; 10019-641; 57884-0028; 10019-644; 10019-646
UNII CRS35BZ94Q
Synonyms Desflurane | 1,2,2,2-Tetrafluoroethyl difluoromethyl ether | I 653 | I-653 | I653 | Suprane
Chemical Information
Molecular Formula C3H2F6O
CAS Registry Number 57041-67-5
SMILES C(C(F)(F)F)(OC(F)F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory depression22.02.01.010; 17.02.05.047--Not Available
Respiratory distress22.02.01.012--Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000179%
Rhabdomyolysis15.05.05.002--
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Tachycardia02.03.02.0070.000179%Not Available
Tachypnoea22.02.01.014--Not Available
Torsade de pointes02.03.04.005--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular tachycardia02.03.04.0100.000179%
Visual acuity reduced17.17.01.011; 06.02.10.012--
Vomiting07.01.07.003--
White blood cell count increased13.01.06.013--Not Available
Tachyarrhythmia02.03.02.008--Not Available
Ventricular hypokinesia02.04.02.013--Not Available
Acute coronary syndrome02.02.02.015; 24.04.04.011--Not Available
Conjunctival hyperaemia06.04.01.004--Not Available
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus07.01.06.026; 09.01.05.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Transaminases increased13.03.04.036--Not Available
Haemorrhage24.07.01.002--Not Available
Ocular icterus06.08.03.009; 01.06.04.007; 09.01.01.007--Not Available
Vasodilation procedure25.03.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Ventricular failure02.05.01.007--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene